

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

- 1-16. (Canceled)
17. (Withdrawn) An antibody or antibody fragment having specific binding affinity to AUR1 and/or AUR2 polypeptide or AUR1 and/or AUR2 domain polypeptide.
18. (Withdrawn) A hybridoma which produces an antibody having specific binding affinity to an AUR1 and/or AUR2 polypeptide.
- 19-20. (Canceled)
21. (Currently Amended) A method of treating ~~at least one disease~~ colon cancer, breast cancer, renal cancer, ovarian cancer, bladder cancer, head and neck cancers, pancreatic cancer, melanoma, glioma, medulloblastoma or chondrosarcoma by administering to a patient in need of such treatment a substance that modulates the kinase activity of ~~at least one~~ a full length AUR-1 ~~or and~~ AUR-2 protein.
22. (Currently Amended) The method of claim 21, wherein said disease is selected from the group consisting of colon cancer, breast cancer, renal cancer ~~and melanoma, ovarian, bladder, head and neck cancers, and gliomas, medulloblastomas, chondrosarcomas, and pancreatic tumors.~~
23. (Currently Amended) The method of claim 21, wherein said disease is ~~selected from the group consisting of colon, breast and renal cancer.~~
24. (Original) The method of claim 21, wherein said substance is an antisense oligonucleotide selected from the group consisting of: SEQ ID NO:30, SEQ ID NO:31, and SEQ ID NO:32.
25. (Original) The method of claim 21, wherein said substance is a protein kinase inhibitor.

26-27. (Canceled)

28. (Withdrawn) An antisense oligonucleotide comprised of a nucleotide base sequence selected from the group consisting of SEQ ID NO:30, SEQ ID NO:31, and SEQ ID NO:32.

29. (Previously Presented) The method according to claim 21, wherein said substance is at least one substance which shows positive results in at least one *in vitro* assay corresponding to treatment of said at least one disease.

30. (Canceled)

31. (Previously Presented) The method according to claim 21, wherein said substance comprises an antisense oligonucleotide.